Advanced Enzyme Technologies Ltd vs Sun Pharma Advanced Research Company Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Advanced Enzyme Technologies Ltd is ₹ 355.6 as of 06 May 15:30 . The P/E Ratio of Advanced Enzyme Technologies Ltd changed from 26.4 on March 2021 to 23.8 on March 2025 . This represents a CAGR of -2.05% over 5 yearsThe P/E Ratio of Sun Pharma Advanced Research Company Ltd changed from -14 on March 2025 to -14 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Advanced Enzyme Technologies Ltd changed from ₹ 3852 crore on March 2021 to ₹ 3120 crore on March 2025 . This represents a CAGR of -4.13% over 5 yearsThe Market Cap of Sun Pharma Advanced Research Company Ltd changed from ₹ 5823 crore on March 2023 to ₹ 4802 crore on March 2025 . This represents a CAGR of -6.22% over 3 years The revenue of Advanced Enzyme Technologies Ltd for the Dec '25 is ₹ 191.66 crore as compare to the Sep '25 revenue of ₹ 194.81 crore. This represent the decline of -1.62% The revenue of Sun Pharma Advanced Research Company Ltd for the Dec '25 is ₹ 8.45 crore as compare to the Sep '25 revenue of ₹ 7.87 crore. This represent the growth of 7.37% The ebitda of Advanced Enzyme Technologies Ltd for the Dec '25 is ₹ 69.07 crore as compare to the Sep '25 ebitda of ₹ 70.34 crore. This represent the decline of -1.81% The ebitda of Sun Pharma Advanced Research Company Ltd for the Dec '25 is ₹ -69 crore as compare to the Sep '25 ebitda of ₹ -65.71 crore. This represent the growth of 5.01% The net profit of Advanced Enzyme Technologies Ltd changed from ₹ 34.98 crore to ₹ 43.18 crore over 7 quarters. This represents a CAGR of 12.79% The net profit of Sun Pharma Advanced Research Company Ltd changed from ₹ -95.9 crore to ₹ -80.42 crore over 7 quarters. This represents a CAGR of -9.57% The Dividend Payout of Advanced Enzyme Technologies Ltd changed from 14.16 % on March 2021 to 56.81 % on March 2025 . This represents a CAGR of 32.03% over 5 yearsThe Dividend Payout of Sun Pharma Advanced Research Company Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that transformed business globally in the manufacturing and sale of enzymes.
The Company was incorporated, as a Private Company on March 15, 1989 as 'Advanced Biochemicals Private Limited' in Maharashtra.
It thereafter converted the status into a Public Company and the name of the Company was changed to Advanced Biochemicals Limited on May 28, 1992 and further was changed to Advanced Enzyme Technologies Limited via fresh Certificate of Incorporation at RoC, Mumbai on August 19, 2005. In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA. In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA. Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders.

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems.
The Company works on innovation and new product development for global markets.
They undertake projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS). Sun Pharmaceutical Advanced Research Company Limited was incorporated on March 1, 2006 as an innovative and development company.
It commenced operations on March 22, 2006.
As per Scheme of Arrangement, the entire business undertaking of the Innovative Research & Development including Novel Drug Delivery System (NDDS) Division of Sun Pharmaceuticals Industries' Research & Development Undertaking was transferred and vested into the Company effective from February 28, 2007.

FAQs for the comparison of Advanced Enzyme Technologies Ltd and Sun Pharma Advanced Research Company Ltd

Which company has a larger market capitalization, Advanced Enzyme Technologies Ltd or Sun Pharma Advanced Research Company Ltd?

Market cap of Advanced Enzyme Technologies Ltd is 3,980 Cr while Market cap of Sun Pharma Advanced Research Company Ltd is 5,096 Cr

What are the key factors driving the stock performance of Advanced Enzyme Technologies Ltd and Sun Pharma Advanced Research Company Ltd?

The stock performance of Advanced Enzyme Technologies Ltd and Sun Pharma Advanced Research Company Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Advanced Enzyme Technologies Ltd and Sun Pharma Advanced Research Company Ltd?

As of May 6, 2026, the Advanced Enzyme Technologies Ltd stock price is INR ₹355.6. On the other hand, Sun Pharma Advanced Research Company Ltd stock price is INR ₹157.05.

How do dividend payouts of Advanced Enzyme Technologies Ltd and Sun Pharma Advanced Research Company Ltd compare?

To compare the dividend payouts of Advanced Enzyme Technologies Ltd and Sun Pharma Advanced Research Company Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.